Who are Ex- vivo cultured adult allogeneic MSCs's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Platelet Rich Plasma (PRP), ACP, Cellular Matrix / A-CP-HA Kit, RAK therapy, IL-2 pre-treated CD19 cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ex-vivo-cultured-adult-allogeneic-mscs.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ex- vivo cultured adult allogeneic MSCs — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ex- vivo cultured adult allogeneic MSCs (Ex- vivo cultured adult allogeneic MSCs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative medicine, Orthopedics.

phase 2 Cell therapy Regenerative medicine, Orthopedics Biologic Live · refreshed every 30 min

Target snapshot

Ex- vivo cultured adult allogeneic MSCs (Ex- vivo cultured adult allogeneic MSCs) — Stempeutics Research Pvt Ltd. Ex- vivo cultured adult allogeneic MSCs are thought to exert their therapeutic effects through paracrine mechanisms, releasing various growth factors and cytokines that promote tissue repair and regeneration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ex- vivo cultured adult allogeneic MSCs TARGET	Ex- vivo cultured adult allogeneic MSCs	Stempeutics Research Pvt Ltd	phase 2	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	Fundación Santiago Dexeus Font	marketed	Cell therapy / Regenerative medicine product
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ex- vivo cultured adult allogeneic MSCs — Competitive Intelligence Brief. https://druglandscape.com/ci/ex-vivo-cultured-adult-allogeneic-mscs. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab